Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: Crispr | History Defined

This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.

Cathie Wood recently added to her position in CRISPR Therapeutics stock.

Barchart

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.

MarketBeat

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Cathie Wood Stocks Analysts Like Better Than Tesla

While Ark Invest scoops up Tesla, these three Cathie Wood picks have higher analyst ratings than the struggling EV leader.

Barchart

1st gene-edited snakes use mysterious 'Turing patterns' to achieve near-perfect hexagonal scales

Scientists used CRISPR editing to make the world's 1st genetically modified snakes, giving new insight into how the reptiles develop their patterned scales

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.